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with il-10-secreting Peripheral 
Blood regulatory T cells
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Jody A. Winter1,2‡ , William Tomlinson1,2 , Joanne Rhead1,2 , Emily Staples1,2 ,  
Kazuyo Kaneko1,2 , John C. Atherton1,2 and Karen Robinson1,2*
1 Nottingham Digestive Diseases Biomedical Research Unit, Queen’s Medical Centre, Nottingham University Hospitals, 
Nottingham, UK, 2 Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
Helicobacter pylori infections are usually established in early childhood and continu-
ously stimulate immunity, including T-helper 1 (Th1), Th17, and regulatory T-cell (Treg) 
responses, throughout life. Although known to be the major cause of peptic ulcer 
disease and gastric cancer, disease occurs in a minority of those who are infected. 
Recently, there has been much interest in beneficial effects arising from infection with this 
pathogen. Published data robustly show that the infection is protective against asthma 
in mouse models. Epidemiological studies show that H. pylori is inversely associated 
with human allergy and asthma, but there is a paucity of mechanistic data to explain 
this. Since Th1 and Treg responses are reported to protect against allergic responses, 
we investigated if there were links between the human systemic Th1 and Treg response 
to H. pylori and allergen-specific IgE levels. The human cytokine and T-cell responses 
were examined using peripheral blood mononuclear cells (PBMCs) from 49 infected and 
58 uninfected adult patients. Concentrations of total and allergen-specific plasma IgE 
were determined by ELISA and ImmunoCAP assays. These responses were analyzed 
according to major virulence factor genotypes of the patients’ colonizing H. pylori strains. 
An in vitro assay was employed, using PBMCs from infected and uninfected donors, 
to determine the role of Treg cytokines in the suppression of IgE. Significantly higher 
frequencies of IL-10-secreting CD4+CD25hi Tregs, but not H. pylori-specific Th1 cells, 
were present in the peripheral blood of infected patients. Total and allergen-specific IgE 
concentrations were lower when there was a strong Treg response, and blocking IL-10 
in vitro dramatically restored IgE responses. IgE concentrations were also significantly 
lower when patients were infected with CagA+ strains or those expressing the more 
active i1 form of VacA. The systemic IL-10+ Treg response is therefore likely to play a role 
in H. pylori-mediated protection against allergy in humans.
Keywords: Helicobacter pylori, allergy, regulatory T cells, interleukin-10, ige
Abbreviations: BFA, brefeldin A; conA, concanavalin A; CTLA-4, cytotoxic T-lymphocyte antigen 4; ECD, phycoerythrin-
Texas Red; GITR, glucocorticoid-induced tumor necrosis factor receptor; IFN, interferon; IL, interleukin; mAb, monoclonal 
antibody; PC5, phycoerythrin cyanin 5.1; PE, phycoerythrin; PMA, phorbol myristate acetate; TGFβ, transforming growth 
factor-beta; Treg, regulatory T-cell.
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inTrODUcTiOn
Helicobacter pylori infection usually becomes established during 
early childhood (1), when the immune system is developing, 
and it persists life-long in the absence of effective treatment (2). 
Peptic ulceration and gastric malignancy may result; however, 
the infection is asymptomatic in the vast majority of cases. In 
recent years, there has been considerable interest in the pos-
sible beneficial effects of H. pylori infection (3–6). Protective 
associations between the infection and risk of atopy, asthma, and 
autoimmunity have been reported in epidemiological studies by 
us and several other groups (7–21). Not all studies have been able 
to demonstrate such trends, however (22–24). A meta-analysis 
of 700 cases and 785 controls could not prove a link between 
H. pylori infection and asthma risk (25), and some researchers 
remain skeptical (26). The most consistently observed protective 
associations with asthma and atopy, however, are in children (8, 
16, 18, 20, 24, 27).
The incidence of atopic disease in developed countries has 
increased markedly over the past 50  years (28, 29). Although 
genetic predisposition is very important, genetic changes cannot 
explain this recent dramatic trend. The worldwide prevalence of 
H. pylori is declining, and fewer children are now infected (6, 
30, 31). In developing countries, such as India and Mexico, the 
infection remains present in over 80% of the population, but in 
many developed countries, the prevalence of H. pylori is now less 
than 20% and it is expected to decline further (32, 33). A role for 
H. pylori in the “hygiene hypothesis” has been suggested, where 
childhood exposure to certain infections is needed for develop-
ment of a healthy immune system (34, 35). Modernization has 
diminished exposure to many of the immunoregulatory stimuli 
that humans have co-evolved with, including intestinal parasites, 
ectoparasites, environmental bacteria, gut commensal organisms, 
and also H. pylori (10, 35–38). It is thought that during the past 
60,000 years, human physiology has developed with the continual 
presence of the bacterium in the stomach (6, 39). There is grow-
ing evidence that adverse consequences may arise from a lack of 
exposure to H. pylori (5).
Allergies occur more commonly when certain immunologi-
cal exposures are absent. Mechanisms include the stimulation of 
 regulatory T cell (Treg) and T-helper 1 (Th1) responses to coun-
terbalance and suppress Th2 activity in atopy (37, 38, 40–42). 
Although the epidemiological evidence for protective associations 
of H. pylori infection with atopy is compelling, it could be argued 
that the infection is simply a marker for other exposures with similar 
risk factors. The first indication of a causal relationship came from 
finding stronger links between childhood asthma and infection 
with more pathogenic CagA+ H. pylori strains (9). Direct proof of 
H. pylori-mediated protection in humans is still lacking, however. 
Arnold et al. were the first to demonstrate in a mouse model that 
H. pylori infection is protective against allergic asthma (43). In 
agreement with the human epidemiological data, these effects were 
stronger when the mice were infected as neonates. The mechanism 
was demonstrated to involve dendritic cell-mediated induction of 
immunosuppressive regulatory T-cells (Tregs), and the H. pylori 
factors important in driving this include vacuolating cytotoxin A 
(VacA), gamma glutamyl transpeptidase (GGT), and urease (44–47).
There is a wealth of published data demonstrating that H. 
pylori infection induces high-level Treg, Th1, and Th17 responses 
in both humans and mouse models (48–53). Interferon-gamma 
(IFNγ)-secreting Th1 cells are associated with increased gastric 
inflammation and disease, whereas Tregs inhibiting inflammation 
are associated with reduced incidence of disease and probably 
contribute to the life-long persistence of H. pylori infections (32, 
48). They are known to be important for suppressing autoimmun-
ity, allergy, and inflammation (54, 55). There are several different 
types of Treg cells, commonly characterized as CD4+, FOXP3+, 
CD127low, and expressing high levels of CD25 (56). Tregs may act 
via a number of mechanisms, including contact-mediated sup-
pression, or secretion of suppressive cytokines, such as interleu-
kin-10 (IL-10), IL-35, or transforming growth factor beta (TGFβ) 
(57–59). IL-10 is known to be protective against allergy, acting via 
inhibition of antigen presentation, down-regulation of effector 
T-cell cytokine expression, and inhibition of mast cell degranula-
tion (42, 60–62). TGFβ is also reported to play a role in protection 
against some animal models of allergy (63, 64). Because of the 
ontogeny of the immune system, H. pylori-infected children tend 
to have stronger Treg responses than adults (65–67). This aligns 
with stronger protection in the neonatally infected mouse allergy 
model (43) and also raises the hypothesis that the elevated fre-
quencies of Tregs present in the circulation of H. pylori-infected 
humans (68) play an important role in protection against allergy.
While a great deal of convincing animal model data exist, it has 
frequently been difficult to prove protective effects of infections, 
including parasites, on clinical atopy and asthma (69). For this 
reason, we decided to look for more subtle effects, studying the 
IgE responses of non-atopic, non-asthmatic patients with care-
fully characterized H. pylori infection status. As reported previ-
ously (68), we found higher frequencies of IL-10-secreting Tregs 
in the peripheral blood of infected patients. Very low plasma 
IgE concentrations were present in those with the highest Treg 
responses, but there were no associations with the Th1 response. 
This indicated that higher levels of H. pylori-induced Tregs are 
associated with reduced markers of allergy. In vitro experiments 
also confirmed that blocking IL-10 (but not IFNγ or TGFβ) 
resulted in significantly increased IgE secretion by peripheral 
blood mononuclear cells (PBMCs) from infected, but not unin-
fected, donors. These data indicate a role for H. pylori-induced 
IL-10-secreting Tregs in protection against human allergy.
MaTerials anD MeThODs
All reagents were obtained from Sigma-Aldrich Ltd. (Poole, UK) 
unless otherwise stated.
ethics statement
Clinical samples were donated with informed written consent 
and approval from Nottingham Research Ethics Committee 2 
(reference 08/H0408/195).
Volunteers and clinical Materials
Samples were donated by 107 patients (aged 19–83 years) under-
going a routine upper gastro-intestinal endoscopy at the Queen’s 
Medical Centre, Nottingham, for a variety of indications (most 
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commonly dyspepsia), but were otherwise healthy. Out of 107 
patients, 49 donors were H. pylori-positive (14 duodenal ulcer, 9 
gastric ulcer, and 26 no ulceration) and 58 were negative (none 
had peptic ulcers). Male-to-female ratios of these groups were 
0.93 and 0.70, respectively; mean ages were 59.7 and 54.6 years, 
respectively. None of the patients were regularly taking non-
steroidal anti-inflammatory drugs or had taken antibiotics or 
proton pump inhibitor drugs in the preceding 2 weeks. None had 
clinically diagnosed asthma or allergies.
A series of biopsies were collected from the gastric antrum for 
determination of H. pylori infection status by urease detection, 
isolation and culture of the organism, and histopathology (48). 
DNA was purified from H. pylori isolates and PCR-genotyping 
carried out to ascertain cagA and vacA genotype status (70, 71). 
The 20-ml peripheral blood samples were collected into EDTA 
vacutainers. Samples of plasma were separated and stored at 
−80°C. PBMCs were purified by density gradient centrifugation 
using Histopaque1077.
Quantification of Treg and Th1-associated 
cytokine responses of human PBMcs
Peripheral blood mononuclear cells at 1  ×  106/ml in AIM V 
medium (Invitrogen) were placed 0.2 ml/well into 96-well plates 
in duplicate. A H. pylori lysate antigen prepared from six clinical 
isolates (48) was added at 25 μg/ml. Negative controls received 
no antigen, whereas positive controls received 5-μg/ml conca-
navalin A (conA) before incubation for 48 h at 37°C in 5% CO2. 
Commercial ELISA kits (eBioscience, Hatfield, UK) were used 
to quantify IL-10 and TGFβ1 in culture supernatants, as per the 
manufacturer’s instructions.
Quantification of Treg and Th1 cells 
in human PBMcs
As described previously (48, 68, 72), 1 × 106 PBMCs were placed 
into culture tubes in RPMI1640 with 10% fetal calf serum (FCS), 
100  U/ml penicillin, and 100  μg/ml streptomycin. H. pylori 
lysate antigen was added at 25 μg/ml, negative controls received 
no antigen, and positive controls received 20  ng/ml phorbol 
myristate acetate (PMA) and 1 μmol/l ionomycin. Brefeldin A 
(BFA) was added to all tubes at 10 μg/ml before 16 h incubation 
at 37°C in 5% CO2.
Cells were stained with anti-CD4-phycoerythrin-Texas Red 
(ECD; Beckman Coulter UK Ltd., High Wycombe, UK) and 
anti-CD25-PE-cyanin 5 (PC5; Biolegend, Cambridge BioScience 
Ltd., Cambridge, UK), with either anti-CD127-phycoerythrin (PE; 
eBioscience, San Diego, CA, USA), anti-CTLA-4-PE (Beckman 
Coulter), or anti-GITR-PE (Biolegend) antibodies in individual 
tubes. Fixed and permeabilized cells were stained with anti-IL-10-PE 
(AbD Serotec, Oxford, UK) and anti-FOXP3-Alexa Fluor®488 
antibody conjugate (Biolegend). The gating of CD25hi was set based 
on the positions of the FOXP3+ and CD127lo populations in CD4+ 
events. Alternatively, cells were stained with anti-CD4-ECD and 
fixed in 0.5% formaldehyde before permeabilization and staining 
with anti-CD69-PC5 and anti-IFNγ-FITC (Beckman Coulter).
Data on 200,000 events were acquired using a Beckman 
Coulter EPICS Altra flow cytometer and analyzed using 
Weasel version 3 (73), with reference to appropriate isotype 
controls.
FOXP3 and IL10 rT-qPcr
The 5 × 106 PBMCs were purified from fresh blood samples using 
Histopaque 1077, and total RNA was extracted using an RNeasy 
minikit (QIAGEN, Crawley, UK), as per the manufacturer’s 
instructions. cDNA was synthesized using SuperScript II reverse 
transcriptase with an oligo(dT) primer (Invitrogen). Real-time 
PCR was performed on a Rotor-Gene 3000 (Corbett Research, 
Cambridge, UK) using primers described in Table  1, with a 
DyNAmo HS SYBR green qPCR kit (New England Biolabs, 
Ipswich, UK) as previously described (48). Amplification was 
over 45 cycles of 15 s at 95°C, 30 s at 62°C, and 30 s at 72°C. No 
template controls were included in each run, and a melting curve 
analysis was performed. First-stage RT-qPCR samples, produced 
without reverse transcriptase, were assayed in parallel. Results 
were analyzed using the Pfaffl method (74). FOXP3 and IL10 
expression levels were normalized against GAPDH, comparing 
to a pooled reference sample from five Hp-negative donors to 
obtain a fold difference. A commercial pooled human cDNA 
standard (BD Biosciences) was included as a positive control in 
all assays.
human ige assays
Plasma IgE concentrations were determined using a Human IgE 
ELISA Quantification Kit (Bethyl, USA) as per the manufac-
turer’s instructions. Optical densities were measured at 450 nm 
with a reference wavelength of 595  nm. Concentrations of IgE 
were determined from a standard curve on each plate. Allergen-
specific IgE assays [timothy grass pollen, birch tree pollen, and 
Dermatophagoides pteronyssinus (house dust mite)] were car-
ried out by the Department of Immunology, Queen’s Medical 
Centre, Nottingham, using the ImmunoCAP system (Phadia AB, 
Uppsala, Sweden).
TaBle 1 | Primer sequences for real-time Pcr.
gene
Primer
Forward reverse
GAPDH CCACATCGCTCAGACACCAT GGCAACAATATCCACTTTACCAGAGT
FOXP3 CAGCACATTCCCAGAGTTCCT GCGTGTGAACCAGTGGTAGAT
IL10 GCTGGAGGACTTTAAGGGTTACCT CTTGATGTCTGGGTCTTGGCT
Sequences are shown in the 5′–3′ orientation.
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In Vitro PBMc culture and Manipulation 
of the cytokine response
A method to induce IgE synthesis in PBMC cultures was 
adapted from previously published studies (75–77). PBMCs 
from 5 H. pylori-positive and 10 H. pylori-negative healthy 
non-allergic donors were resuspended in RPMI 1640 medium 
(supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 50 μg/ml transferrin, and 4 μg/ml insulin). The 
200-μl aliquots containing 3 × 105 cells were added to the wells 
of a sterile 96-well polystyrene round-bottomed plate (Thermo 
Scientific). In order to induce Th2-skewed conditions, rIL-4 and 
sCD40L were added to the cells at final concentrations of 50 μg/
ml and 100 ng/ml, respectively (Peprotech). The PBMCs were 
cultured for 12 days at 37°C and 5% CO2. Supernatants were then 
removed and stored at −80°C.
In order to observe the effects of IL-10 and TGFβ on IgE syn-
thesis, on day 0 of the culture, 20-μl recombinant human IL-10 
(rIL-10) (AbD Serotec) or rTGFβ (AbD Serotec) were added 
at various concentrations to appropriate wells in quadruplicate 
(76). The equivalent volume of medium was added to control 
wells. Cytokines were blocked by adding anti-IL-10 (rat IgG1 
clone JES3-9D7, eBioscience) and anti-TGFβ (mouse IgG1 clone 
1D11, Abcam) mAbs at varying concentrations. The respective 
isotype control antibodies were added at the equivalent concen-
trations. The 20-μg/ml JES3-9D7 has previously been shown to 
efficiently neutralize endogenously produced IL-10 in a similar 
culture system (77). The neutralization dose (ND50) of 1D11 
antibody is typically 0.25–1.25 μg/ml in the presence of 1 ng/ml 
recombinant human TGFβ1 (78). The PBMCs were then cultured 
for 12 days at 37°C with 5% CO2 before collection and assay of 
the supernatants for IgE.
statistical analysis
Statistical analyses were carried out using Prism 6.00 (GraphPad 
Software, CA, USA). Since the data were not normally distrib-
uted, non-parametric analysis methods were used. Statistical tests 
of paired data were carried out using the Wilcoxon signed rank 
test. For unpaired data, the Mann–Whitney U-test was used. A 
significant difference was taken at p ≤ 0.05.
Box and whisker plots depict the medians and interquartile 
ranges in the boxes, with whiskers extending to the maximum 
and minimum points in the data.
resUlTs
Peripheral Blood Th1 and Treg responses 
in infected and Uninfected Patients
Previous work showed a high-level Treg and Th1 response in the H. 
pylori-infected human gastric mucosa and significantly increased 
numbers of CD4+CD25hi Tregs in peripheral blood (48, 68). We 
further investigated the circulating Treg population and deter-
mined if higher numbers of Th1 cells were also present. We began 
by quantifying the cytokines IFNγ, IL-10, and TGFβ1 in PBMC 
culture supernatants from infected and uninfected patients, and 
comparing the frequencies of Treg and Th1 cells by flow cytometry. 
PBMCs from all patients secreted IFNγ when stimulated with 
H. pylori lysate antigen (Hp) (Figure 1A) or the positive control 
mitogen conA; however, the concentrations were higher (median 
difference: 3.6-fold) among the Hp-stimulated supernatants from 
infected compared to uninfected individuals (p =  0.05). This is 
indicative of a systemic Th1 response to Hp infection. Similarly, 
there were slightly higher concentrations of IL-10 (median: 1.3-
fold, p = 0.02), but there were no differences in TGFβ1 levels.
Using flow cytometry to quantify Hp-specific Th1 cells, 
we immunostained for the early activation marker CD69 (72) 
and analyzed cells that were activated by Hp lysate antigen 
(Figure  1B). Higher frequencies of CD69hiCD4+ events were 
obtained from the Hp-stimulated PBMCs of infected compared 
to uninfected donors (median: Hp+ 10.1%, Hp− 4.9%; p = 0.001), 
demonstrating a higher frequency of Hp-specific systemic T-cells 
during infection (data not shown). When cells from both infected 
and uninfected donors were stimulated with Hp, there was a 
significantly increased frequency of CD69hiCD4+IFNγ+ events 
compared to unstimulated PBMCs (paired analyses: infected 
p = 0.005; uninfected p = 0.001; Figure 1C), and similar statisti-
cally significant trends were found following PMA/ionomycin 
stimulation. No significant differences in the responses of cells 
from infected and uninfected donors were found; therefore, 
we could not confirm an increased frequency of Th1 cells in 
the peripheral blood of the infected patients. There were also 
no differences according to the cagA virulence genotype of the 
colonizing bacterial strains (not shown).
To quantify the Treg response, CD25hi staining was taken as 
a higher intensity of fluorescence compared to that observed for 
CD4 negative cells (Figure 2A), included the FOXP3+ and IL-10+ 
populations (Figures  2B,C), and corresponded with the CD25 
staining intensity in the CD127lo population (Figure  2D). As 
expected, not all CD4+CD25hi events expressed FOXP3. 48–81% 
of gated CD4+CD25hiIL-10+ events were FOXP3+ (Figure 2E). A 
2.5-fold higher median frequency of CD4+CD25hi cells (p = 0.002) 
was present in PBMCs from infected patients (Figure 3A). There 
was also a 2.5-fold increased level of IL-10+ CD4+CD25hicells 
(p = 0.007; Figure 3B). There was a modest 1.7-fold increase in 
the frequencies of CD4+CD25hiCTLA-4+ cells (p =  0.007, data 
not shown), but there was no difference in the frequencies of 
CD4+CD25hiGITR+ cells (not shown). The proportion of FOXP3+ 
events among CD4+CD25hi cells was not different between 
infected and uninfected donors, or with/without antigen stimu-
lation (Figure 3C), and FOXP3 mRNA levels were no different 
when assaying PBMCs by RT-qPCR (Figure 3D). The variation 
in FOXP3+ cell frequencies was extremely wide within both the 
infected and the uninfected groups, which hampered our ability 
to detect statistically significant differences. The frequencies of 
IL-10+ and FOXP3+ CD4+CD25hi cells and the corresponding 
IL10 and FOXP3 transcript levels did not vary significantly 
according to the age or gender of the patient groups; however, those 
with gastric or duodenal ulcers had significantly lower frequen-
cies of CD4+CD25hi cells than who only had gastritis (medians: 
1.80 and 3.89%, respectively; p = 0.047). Similar findings were 
obtained when analyzing CD4+CD25hiIL-10+ data (medians: 0.10 
and 0.17%, respectively; p = 0.041). In contrast, the proportion 
of FOXP3+ events among CD4+CD25hi cells was not significantly 
different with respect to peptic ulcer disease status among the 
infected group. Stimulating PBMCs from infected patients with 
FigUre 1 | Peripheral blood Th1 and Treg cytokine responses in H. pylori-infected and uninfected patients. (a) PBMCs from 13 infected patients (white 
bars) and 11 uninfected patients (gray bars) were cultured for 48 h in the presence of 25 μg/ml H. pylori (Hp) lysate, with medium alone as a negative control or with 
20 μg/ml conA as a positive control stimulus. IFNγ, IL-10, and TGFβ1 concentrations were determined using commercial ELISA kits. Bars depict the median and 
error bars show the 95% confidence interval. Following conA stimulation, median concentrations from the PBMCs of infected and uninfected patients were, 
respectively, 1885 and 2035 pg/ml IFNγ, 375 and 393 pg/ml IL-10, and 352 and 306 pg/ml TGFβ1. Th1 cells were quantified in PBMCs from 34 infected and 24 
uninfected patients using flow cytometry. (B) Example flow cytometry dot plots of gated CD4+ cells from an infected donor, stained for CD69 and IFNγ after culture 
of PBMCs in medium alone, or with Hp lysate antigen. Quadrant indicates the position of CD69hi IFNγ+ events, with the lower left quadrant containing both 
CD69-negative and -positive events. (c) The percentage of CD4+CD69hi IFNγ+ events among PBMC lymphocytes is shown following culture in medium alone 
(unstimulated) or with Hp lysate antigen. When stimulated with PMA and ionomycin as a positive control stimulus, the median percentages of CD4+CD69hiIFNγ+ 
events in PBMCs from infected and uninfected donors were 1.13 and 1.17%, respectively. The percentages of CD4+CD69hiIFNγ+ events were not significantly 
different between Hp-stimulated samples from infected and uninfected donors.
March 2016 | Volume 7 | Article 715
Hussain et al. H. pylori Protection against Allergy
Frontiers in Immunology | www.frontiersin.org
Hp antigen resulted in a significant increase in the proportion of 
Tregs secreting IL-10 (p = 0.01), but there was no significant effect 
on cells from uninfected patients (Figure 3E). This indicates that 
H. pylori infection induces a specific IL-10-secreting peripheral 
blood Treg response. IL10 mRNA levels in freshly isolated PBMCs 
from infected patients were 3.8-fold higher than the uninfected 
group (p =  0.001; Figure  3F), and there was a 4.8-fold higher 
mRNA level in the samples from infected patients without peptic 
ulcer disease compared to those who had ulcers (p =  0.017). 
These data confirm the presence of increased numbers of IL-10+ 
cells in the circulation of H. pylori-infected patients, particularly 
when peptic ulceration is absent. Since there was an elevated 
systemic IL-10-secreting Treg response in infected patients, we 
hypothesized that as in the mouse, this could be an important 
mechanism behind the protective associations with allergy.
association between the human 
regulatory T-cell and ige responses
Total and allergen-specific IgE concentrations in the plasma of 
49 infected and 46 uninfected patients were not significantly dif-
ferent (Table 2); however, among the infected group, there were 
differences in total IgE according to the virulence genotype of 
the colonizing H. pylori strains. This was important to evaluate, 
since presence of a strain expressing CagA has previously been 
reported to be associated with greater protection against asthma 
(9). VacA is known to be protective against allergy in mice 
(45). Since cagA+ strains usually also express the most active 
i1 form of vacA (71), we investigated how IgE levels related to 
these virulence factors. Apart from in five cases, the 29 cagA+ 
strains were also of the more active vacA i1 type. All but 5 of 
the 20 less pathogenic cagA− strains were typed as having the 
FigUre 2 | example flow cytometry dot plots to display the gating and designation of cD25hi cells among PBMc lymphocytes. CD25hi events were 
gated on the basis that expression is of higher intensity in CD4+ events (a). Among gated CD4+ events, the CD25hi population contains FOXP3+ events (B), IL-10+ 
events (c), and corresponds to the CD127lo population (D). Among gated CD4+CD25hi events, the majority of IL-10+ events were also FOXP3+ (e).
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less active i2 form of vacA. We were therefore unable to pick 
apart the roles of these factors individually. The patients infected 
with the more virulent cagA+ or vacA i1 strains had threefold 
lower concentrations of IgE compared to those with cagA− or 
vacA i2 strains (Figure 4; p = 0.005 and p = 0.029, respectively). 
Surprisingly, however, there were no significant differences in 
Treg frequencies or IL-10 transcripts between those with cagA+ 
versus cagA– strains, and the same result was found for vacA 
genotypes (data not shown).
When comparing the magnitude of the Treg response with 
IgE levels, we observed some interesting trends. Patients with the 
highest frequencies of CD4+CD25hi PBMCs had the lowest total 
IgE concentrations. The effect was stronger among the samples 
from H. pylori-positive patients (Figures 5A,C), where having a 
high-level Treg response was more common. The data were strati-
fied according to whether or not CD4+CD25hi cell frequencies 
were above or below 10%, which equated to the mean + 1 SD of all 
samples tested and was well above the normal range for frequen-
cies of these cells in peripheral blood as previously reported in 
other studies (79, 80). Among the samples from infected patients 
with high CD4+CD25hi cell frequencies, there was a fivefold lower 
median IgE concentration, compared to those with frequencies 
below 10% (p =  0.001) (Figure 5C). Among the samples from 
infected patients with high IL-10+ CD4+CD25hi cell frequencies 
(>0.4%, mean + 1 SD), similarly there was a fivefold lower median 
IgE concentration, compared to those with low IL-10+ Treg 
frequencies (p = 0.01) (Figure 5B,D). There was no significant 
difference in the total plasma IgE concentrations of uninfected 
patients with high and low Treg frequencies (Figures 5C,D).
A significantly reduced grass (p = 0.004) and birch (p = 0.002) 
pollen-specific IgE concentration was present among infected 
patients with high frequencies of peripheral blood Treg cells 
(Table  3), but there were no significant differences among the 
uninfected group, or with regard to house dust mite-specific IgE. 
Similar trends were observed when comparing IgE concentra-
tions with frequencies of IL-10+CD4+CD25hi PBMCs (data not 
shown). There were no significant trends when PBMC Th1 
responses were compared with IgE levels (data not shown). 
Together, these data indicate that H. pylori infection is associated 
with unusually high circulating Treg levels, which could perhaps 
directly or indirectly suppress IgE production and influence the 
development of allergy.
FigUre 3 | regulatory T-cells in the peripheral blood of 49 H. pylori-infected and 58 uninfected patients. The percentage of CD4+CD25hi events among 
gated lymphocytes (a). For determination of IL-10+CD4+CD25hi Tregs (B), PBMCs were cultured in the presence and absence of Hp lysate antigen. Median 
frequencies of IL-10+CD4+CD25hi events among unstimulated cells were 0.04% (uninfected donors) and 0.04% (infected donors). The proportion of CD4+CD25hi 
cells expressing FOXP3 (c) and IL-10 (e) was assessed in PBMCs cultured with and without Hp lysate antigen (Unstim and Hp-stim, respectively). RT-PCR was 
performed on freshly isolated PBMCs from 48 infected and 26 uninfected patients to quantify FOXP3 (D) and IL10 (F) mRNA expression levels. Data were 
normalized relative to GAPDH expression. NS = no significant difference.
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TaBle 2 | Total and allergen-specific ige levels in the plasma of 49 
infected and 46 uninfected patients.
ige measurement Median concentration and  
interquartile range
H. pylori-positive H. pylori-negative
Total (ng/ml) 58.7 (22.1–140.1) 31.4 (9.61–133.3)
House dust specific (kUA/l) 0.05 (0.03–0.13) 0.04 (0.02–0.21)
Grass pollen specific (kUA/l) 0.00 (0.00–0.03) 0.00 (0.00–0.03)
Birch pollen specific (kUA/l) 0.01 (0.00–0.02) 0.00 (0.00–0.01)
March 2016 | Volume 7 | Article 718
Hussain et al. H. pylori Protection against Allergy
Frontiers in Immunology | www.frontiersin.org
infected (medians 25.8 and 34.2 pg/ml, respectively; p = 0.013; 
Figure 6A). The concentrations of IL-10 were fivefold higher in 
the supernatants of PBMCs from the infected donors (p = 0.055; 
Figure 6B), but there were no differences in the concentrations of 
TGFβ1 (Figure 6C).
The cultures were also performed in the presence or absence 
of varying concentrations of recombinant IL-10, TGFβ1, or 
antibodies known to block the function of these cytokines. A 
range of concentrations was used so that we could investigate if 
there was a dose–response effect. Comparing each treatment to 
the non-treated control for each donor, the percentage decrease 
in total IgE resulting from the addition of recombinant cytokines 
was calculated. Adding the recombinant cytokines, at a range 
of concentrations reported previously to potently interfere with 
human T-helper cell activity (76, 81), caused a dose-dependent 
reduction in IgE secretion by PBMCs from both H. pylori-positive 
and -negative donors (Figures 7A,B). rIL-10 appeared to have a 
more potent effect than rTGFβ. Adding as little as 10 ng/ml rIL-
10 resulted in a median 31% reduction in IgE concentration in 
the cultures compared to controls without rIL-10 (p =  0.020). 
Adding 20 ng/ml rIL-10 resulted in a median 52% reduction in 
IgE (p = 0.001). In contrast, a significantly reduced IgE concentra-
tion could only be achieved using the highest concentration of 
100 ng/ml rTGFβ (5% reduction compared to no rTGFβ controls, 
p = 0.041). No differences in IgE response could be found between 
the PBMCs from H. pylori-positive and -negative donors in these 
assays however.
Adding IL-10 mAb, at a range of concentrations reported pre-
viously to block cytokine activity (77, 78), resulted in increased 
IgE production by PBMCs from both groups (H. pylori-positive 
and -negative donors), compared to cultures with the equivalent 
concentration of isotype control antibodies (Figure 7C). Adding 
anti-TGFβ had very little effect (Figure  7D). The difference in 
the size of the effect from IL-10 blockade between H. pylori-
positive and -negative donors was statistically significant (20 μg/
ml: 24%, p = 0.02; 40 μg/ml: 53%, p = 0.006). Therefore, we had 
confirmation that blocking IL-10, which was present at higher 
concentrations in the isotype control cultures of PBMCs from H. 
pylori-positive donors (Figure 6B), had a pronounced suppres-
sive influence on IgE production in vitro.
DiscUssiOn
This study aimed to further investigate the inverse association 
between H. pylori infection and allergy in humans, and fill an impor-
tant gap in current literature by exploring the potential mechanisms 
behind this. We were able to demonstrate a link between IL-10-
secreting peripheral blood Treg cell numbers and the concentration 
of IgE in the plasma of infected patients, and we also showed that 
IL-10 produced by leukocytes from those with H. pylori played an 
important role in controlling IgE production in vitro.
Our previous work found an increased Treg and Th1 response 
in the H. pylori-infected human gastric mucosa (48) and higher 
frequencies of Tregs in the peripheral blood of infected patients 
(68). These cell types have previously been implicated in the 
suppression of Th2 responses and allergy. We hypothesized that 
increased levels of Treg cells and/or Th1 cells in the circulation 
FigUre 4 | Plasma ige concentrations from 49 patients infected with 
H. pylori strains of differing virulence genotypes. Of the 29 cagA+ 
strains, 24 were of the i1 vacA genotype and 5 were vacA i2. Of the 20 
cagA− strains, 15 were vacA i2 and 5 were of the vacA i1 genotype. Points 
represent the results from individuals and horizontal lines depict the median.
Mechanistic experiments to investigate 
the role of Th1 and Treg cytokines in the 
suppression of ige
To test the previously observed associations between H. pylori 
infection, serum IgE levels and abundance of peripheral blood 
Treg cells, an in  vitro culture system was employed. PBMCs 
from 5 infected and 10 uninfected healthy donors (all without 
ulcers) were cultured under Th2-skewing conditions [with IL-4 
and rCD40L (75)] for 12  days. Total IgE, IL-10, and TGFβ1 
concentrations in the culture supernatants were then measured 
by ELISA. These culture conditions were used to investigate the 
hypothesis that PBMCs from H. pylori-positive donors would 
be inherently less able to respond to the Th2 stimulation com-
pared to those from H. pylori-negative donors, possibly due to 
IL-10 or TGFβ inhibition of IgE production in vitro. The culture 
system provided an opportunity to investigate the consequence 
of adding or selectively blocking IL-10 and TGFβ. From the 
in vivo data, we hypothesized that blocking IL-10 would increase 
IgE production more markedly when the PBMCs were from H. 
pylori-positive donors. As anticipated, IgE concentrations were 
lower for the infected donors compared to those who were not 
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influence immune responses at extra-gastric sites in the body and 
may play a role in preventing an elevated IgE response. Initially, 
we compared the IFNγ, IL-10, and TGFβ1 responses of PBMCs 
to stimulation with Hp lysate antigen. Enhanced concentrations 
of IFNγ [as shown previously (82)] and IL-10 were found in 
the PBMC supernatants from infected patients, indicating that 
peripheral blood Th1 and Treg responses were increased. Cells 
from both H. pylori-positive and -negative patients secreted IFNγ 
and IL-10 in response to Hp lysate antigens, indicating that the 
response was not antigen specific. Flow cytometry was therefore 
used to determine whether increased frequencies of Th1 and Treg 
cells were present in the blood of infected patients.
Our experiments employed detection of CD69 expression, 
an early activation marker (83), as a tool to identify IFNγ+CD4+ 
Th1 cells that were responsive to Hp stimulation. This could be 
a consequence of antigen-specific reactivation of memory cells 
or T-cell receptor-independent immune activation. In agreement 
with the work of Lundgren et  al. (84), peripheral blood CD4+ 
cells secreted IFNγ when stimulated with Hp antigen; however, 
there were no differences between the samples from infected and 
uninfected donors. The response is therefore unlikely to be due 
to reactivation of H. pylori-specific memory cells, but could arise 
because of shared or cross-reactive antigens with other bacteria, 
or because ligands for pattern recognition receptors were present 
in the antigen preparation (85).
In agreement with our previous work, and that of others, we 
found higher levels of CD4+CD25hi lymphocytes among PBMCs 
from the infected donors (68, 84). It was necessary to determine 
if these populations could be classed as Tregs by using a selection 
of cellular markers, and a large proportion of the CD4+CD25hi 
events expressed FOXP3 and/or IL-10. Since enhanced FOXP3+ 
Treg levels are present in the infected human gastric mucosa (48, 
49, 51), we were surprised to find no difference in the frequencies 
FigUre 5 | association between human peripheral blood regulatory T-cells and the ige response. The frequency of CD4+CD25hi (a) and IL-10+ 
CD4+CD25hi Tregs (B) in PBMCs from 49 infected and 46 uninfected donors was assessed by flow cytometry after 15 h culture with Hp lysate antigen. This was 
compared to the total plasma IgE concentration for each patient. The data were divided according to whether there were high (>10%) or low frequencies of 
CD4+CD25hi lymphocytes (c) and high (>0.4%) or low frequencies of IL-10+CD4+CD25hi events (D) to further examine associations with total IgE concentrations. 
NS = no significant difference.
TaBle 3 | allergen-specific ige levels in the plasma of 49 infected and 
46 uninfected patients with high and lower peripheral blood cD4+cD25hi 
cell frequencies.
Median concentration (kUa/l) and interquartile range
house dust grass pollen Birch pollen
H. pylori 
infected
NS p = 0.004 p = 0.002
High Treg 
frequencies
0.06 (0.03–0.14) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Lower Treg 
frequencies
0.05 (0.04–0.13) 0.02 (0.00–0.18) 0.01 (0.00–0.02)
Uninfected NS NS NS
High Treg 
frequencies
0.03 (0.03–5.74) 0.00 (0.00–0.04) 0.00 (0.00–0.02)
Lower Treg 
frequencies
0.04 (0.02–0.09) 0.00 (0.00–0.03) 0.00 (0.00–0.02)
Allergen-specific IgE data were stratified according to whether the patient had a high 
Treg response (>10% CD4+CD25hi PBMCs) or if the frequency was below this level. 
A Mann–Whitney U-test analysis was performed to examine differences in the IgE 
responses of these groups. NS = no significant difference.
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of FOXP3+CD4+CD25hi PBMCs, but this result was confirmed 
using RT-qPCR. FOXP3 is not a completely reliable marker for 
human Tregs, since its expression can be induced in activated 
cells that lack suppressive function, and not all Treg populations 
are FOXP3+ (56, 86). Interestingly, we were able to show increased 
levels of CD4+CD25hiIL-10+ lymphocytes in the PBMCs of 
infected patients. When stimulating PBMCs with Hp lysate 
antigen, a higher proportion of the Tregs from H. pylori-positive 
patients expressed IL-10. There was no effect on the CD4+CD25hi 
population from uninfected patients, indicating the presence of 
a H. pylori-specific circulating Treg response. We were also able 
to confirm this by RT-qPCR, where higher levels of IL10 mRNA 
were found in PBMCs from the infected patients. This agrees with 
several previous reports of H. pylori-specific IL-10-secreting CD4+ 
FigUre 6 | culture of PBMcs under Th2-skewing conditions. PBMCs 
from 5 infected and 10 uninfected donors were cultured for 12 days before 
assaying the supernatants for total IgE (a), IL-10 (B), and TGFβ1 (c) by 
ELISA. NS = no significant difference.
cells in the blood (87–89). We previously found increased levels 
of IL-10+FOXP3+ Tregs in the H. pylori-infected human gastric 
mucosa, cellular FOXP3 expression was of high level and could be 
confirmed by RT-qPCR (48). Our data suggest that slightly differ-
ent Treg populations may be present in the blood, and these could 
include a higher proportion of FOXP3− subtypes, such as Tr1 cells 
(which are IL-10+) (90) and FOXA1+ cells (associated with IFNβ 
responses) (91), since H. pylori stimulates the production of IFNβ 
by gastric epithelial cells (92). Recently, we were able to show that 
significantly higher proportions of peripheral blood Tregs from 
infected patients expressed the chemokine receptor CCR6 and 
that high concentrations of its ligand, CCL20, were present in 
infected human gastric mucosal tissue. The CCL20–CCR6 axis 
was shown to play an important role in the migration of Tregs 
to the infected gastric mucosa (68). Some studies have suggested 
that CCL20/CCR6 interactions are important in the development 
of Th2 responses and allergy (93, 94). It may therefore be the case 
that CCR6+ Tregs in the circulation of those infected with H. pylori 
are more capable of migration to the site of allergic responses.
Increased concentrations of IL-10 (but not IFNγ) are present in 
the serum of H. pylori-infected patients (95), and we have found 
high levels of Hp-specific IL-10-secreting Tregs in the circula-
tion. This makes it a likely possibility that such cells could cause 
bystander suppression of other unrelated extra-gastric immune 
responses via IL-10 secretion. Since the major function of Tregs is 
to prevent autoimmune disease caused by an overzealous immune 
response (58), we hypothesized that the H. pylori-induced Treg 
response is involved in protection against allergy. Increased IL-10 
responses have been postulated as a mechanism behind H. pylori-
mediated protection from allergy in humans (96); however, Cam 
et al. found that PBMC IL-10 production was not influenced by 
H. pylori status or presence of atopy in children (97). Because of 
these controversies, we examined the relationship between plasma 
IgE concentrations and the frequency of IL-10+ CD4+CD25hi 
Tregs among PBMCs in infected and uninfected individuals. No 
significant differences in IgE concentrations (total or antigen spe-
cific) were found between the groups of infected and uninfected 
donors. This may be due to collecting samples from patients with 
GI symptoms, where only a small proportion had concentrations 
of serum IgE above the normal range, and none had reported that 
they suffered from allergies or asthma. When associations between 
Treg frequency and plasma IgE concentration were examined, as 
anticipated from the literature (76, 98), higher Treg responses 
coincided with low IgE levels. This trend was exaggerated among 
the H. pylori-positive group, which contained more individuals 
with high Treg frequencies accompanied by lower concentrations 
of total, grass pollen-, and birch pollen-specific IgE. The trend was 
not statistically significant among the uninfected group, indicating 
that stronger Treg responses in H. pylori infection may suppress 
IgE levels. We acknowledge that as the samples were collected 
throughout the year, the data are likely to be confounded by sea-
sonal variation in exposure to pollens. Regardless of this, we were 
able to detect significant differences in the relationship between IgE 
and circulating Tregs between the infected and uninfected groups.
Blaser et al. reported stronger protective associations between 
childhood asthma and more virulent CagA+ H. pylori infections 
(7, 9). Our data supported this finding, since those infected with 
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cagA+ strains had threefold lower plasma IgE concentrations. 
A number of H. pylori virulence factors have been reported to 
influence the development of allergy in mouse models, includ-
ing H. pylori neutrophil-activating protein (HP-NAP) (a potent 
stimulator of Th1 responses) and VacA (known to interfere with 
antigen presentation and to inhibit T-cell activation; also proposed 
to stimulate Tregs) (45, 99, 100). Strains which express the active 
i1 form of VacA are usually also cagA+ and those expressing the i2 
form of VacA are usually cagA− (101). This was indeed true in 39/49 
of our clinical isolates and, since the vacA types also followed the 
same trend in the IgE data, we consider it likely that the reported 
stronger protection from CagA+ strains against childhood asthma 
could actually have been driven by VacA, with CagA acting as a 
marker for this. We previously found elevated IL-10 responses in 
the cagA+-infected gastric mucosa (48), but in the present study, 
we could not find a corresponding significant difference in the 
peripheral blood (data not shown). It has been suggested that cagA+ 
strains may elicit an increased gastric Treg response to modulate 
the heightened inflammation, but that there is also a pronounced 
effect on the migration of Tregs, which may have an impact on the 
populations found in peripheral blood (68, 102).
We performed experiments with an in vitro culture system to 
investigate the impact of IL-10 and TGFβ on IgE production in a 
well-controlled manner. The healthy donors who provided us with 
blood samples did not have different plasma IgE concentrations 
according to their H. pylori status (data not shown); therefore, these 
experiments allowed us to investigate the potential for their PBMCs 
to be influenced by a Th2-skewing treatment and produce IgE 
in vitro. The cells from the uninfected donors secreted significantly 
higher IgE concentrations, while producing markedly lower levels 
of IL-10. This implies that there were marked differences in the 
PBMC cell populations of infected and uninfected donors and is in 
agreement with the increased frequencies of IL-10-secreting Tregs 
among those with H. pylori. When rIL-10 was added to the cultures, 
in accordance with previous data, the PBMCs produced lower 
amounts of IgE (76). This occurred whether the cells were from 
infected or uninfected donors. When IL-10 blocking antibody was 
added, however, there was a significantly increased IgE response, 
which was especially marked when PBMCs were from infected 
donors. There were minimal effects from rTGFβ1 or TGFβ antibody 
blockade. These experiments demonstrate the important role of the 
H. pylori-induced IL-10 response in controlling IgE production.
FigUre 7 | influence of recombinant il-10 and TgFβ or their blocking antibodies on the in vitro ige response of PBMcs from H. pylori-infected and 
-uninfected donors. PBMCs from 5 infected and 10 uninfected donors were cultured for 12 days under Th2-skewing conditions, with the addition of rIL-10 (a), 
rTGFβ (B), anti-IL-10 (c), or anti-TGFβ (D) blocking monoclonal antibodies. Equivalent volumes of medium were added to further wells as controls for recombinant 
cytokines; equivalent concentrations of isotype control antibodies were added as controls for the cytokine-blocking antibodies. Total IgE concentrations were 
assayed by ELISA and the percentage change was calculated for each individual with respect to the control cultures. Points represent the results from individuals 
and horizontal lines depict the median.
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